Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis

This study aimed to compare the effects of abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy (ADT) with those of combined androgen blockade (CAB) therapy in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). This study retrospectively identified 1...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Naoki Matsumura, Kazutoshi Fujita, Mitsuhisa Nishimoto, Yutaka Yamamoto, Ken Kuwahara, Yasuharu Nagai, Takafumi Minami, Yuji Hatanaka, Masahiro Nozawa, Yasuhiro Morimoto, Hideo Tahara, Shigeya Uejima, Atsunobu Esa, Akihide Hirayama, Kazuhiro Yoshimura, Hirotsugu Uemura
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2021-12-01
Rangatū:	Frontiers in Oncology
Ngā marau:	prostate cancer metastatic hormone-sensitive prostate cancer abiraterone acetate combined androgen blockade high risk prostate cancer
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fonc.2021.769068/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!